The James Russell Revocable Trust has made a significant move by filing a Schedule 13D regarding its ownership in Abeona Therapeutics Inc. The filing reveals that the trust now holds approximately 6.1% of the company’s common stock, indicating a shift from a passive investment strategy to a more active role in the company’s governance.
This development is noteworthy as it comes amid concerns raised by the trust regarding Abeona's operational execution and the consistency of management's public statements with actual operating results. The trust's trustee, James Russell, has expressed intentions to engage with the company's board to discuss these issues, which may lead to potential changes in leadership or board composition.
Background
Abeona Therapeutics Inc. is a pharmaceutical company focused on developing gene and cell therapies for rare diseases. The company is headquartered in Cleveland, Ohio, and operates under the Central Index Key (CIK) 0000318306. The trust, which is based in Las Vegas, Nevada, has been involved with Abeona for some time, previously reporting its beneficial ownership in a Schedule 13G filing.
What the Filing Says
In the recent Schedule 13D filing dated October 23, 2026, the trust indicated that it has acquired a total of 3,479,963 shares of Abeona, which were purchased with personal funds totaling approximately $17.8 million. The filing states, "The Reporting Persons originally acquired the Shares for investment purposes and reported their beneficial ownership on Schedule 13G... Over time, based on their review of the Issuer's public filings, press releases and other public communications, the Reporting Persons became concerned regarding the Issuer's operational execution..."
Impact
This increased stake and the shift to an active investment strategy may affect not only Abeona's management but also its shareholders and potential investors. The trust's concerns about governance and operational execution could lead to increased scrutiny of the company's practices and decisions. Additionally, the trust has indicated plans to communicate with other shareholders, which may further influence the company's direction.
What's Next
The filing does not specify what actions the trust may take next, but it suggests ongoing engagement with Abeona's board and management regarding the company's affairs. Depending on the board's response to the trust's concerns, further actions could include proposing new board members or voting against incumbent directors at the upcoming annual meeting.
Source: SEC Filing Accession Number 0001477932-26-006433